The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InNorthStar Medical Radioisotopes has achieved a significant regulatory milestone with the FDA's acceptance of its Type II Drug Master File (DMF) for no-carrier-added Actinium-225 (Ac-225). This acceptance allows pharmaceutical partners to reference NorthStar’s proprietary manufacturing processes in their own drug applications and clinical trials. Actinium-225 is a critical radioisotope used in the development of targeted radiopharmaceutical therapies, particularly in oncology. By securing this DMF, NorthStar provides a reliable and scalable supply chain for a sector often hampered by material shortages. The move validates the company's production technology and is expected to accelerate the development of next-generation cancer treatments. While NorthStar remains a private entity, this development serves as a bullish indicator for the broader radiopharmaceutical industry and its listed partners.